While there are significant data and methodological challenges to be overcome, there are better alternatives to simplistically extrapolating from the real-world data on AOM use that is currently available.
Medicare and Medicaid
Other featured articles
Government And Commercial Insurer Payment Rates to Hospitals: A Commentary on Priselac
Paul Ginsburg from discusses how for decades, stakeholders have argued about whether competition or regulation should be the approach to constrain health care spending. By having chosen neither, he argues, our nation now finds itself with a much larger challenge. The magnitude of our health care affordability problem cries out for pursuing both competition and regulation.
Healthcare Utilization Before and After a Dementia Diagnosis in Medicare Advantage Versus Traditional Medicare
The increase in care use leading up to a dementia diagnosis is higher among beneficiaries in traditional Medicare than in Advantage plans and remains higher after diagnosis.
White House Names First 10 Drugs for Medicare Negotiations; USC Policy Experts Available to Discuss Market Impact
Medicare released the list of the first 10 drugs subject to price negotiations under the Inflation Reduction Act (IRA), aiming to reduce drug costs for Medicare enrollees and taxpayers.
Estimates of Diagnosed Dementia Prevalence and Incidence Among Diverse Beneficiaries in Traditional Medicare and Medicare Advantage
The prevalence of diagnosed dementia among beneficiaries in MA was lower than in TM.
About this section
The nation’s growing debt threatens Medicare and Medicaid, which have helped countless Americans and reduced poverty. Schaeffer Center researchers work with legislators on a bipartisan basis to bolster these vital systems, making them more efficient and effective.